Actively Recruiting
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD)
Led by University of Michigan · Updated on 2026-04-29
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the course and recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after kidney transplant. These conditions can lead to complications like reduced quality of life, edema, early graft loss, and mortality. The study aims to improve understanding of these diseases by collecting detailed information and biospecimens from patients who have had or will have a kidney transplant, enabling better research into their causes and outcomes. This observational study enrolls participants before or after transplant and also includes retrospective data from those transplanted since 2000. It collects clinical data, patient-reported information, and biospecimens such as urine, blood, saliva, and kidney tissue to create a biobank. Different enrollment options allow researchers to study the incidence, prevalence, and post-transplant progression of FSGS and MCD. Participants provide consent for data and biospecimen collection or are included through a waiver for existing data use. The study tracks outcomes like time to disease recurrence and graft failure over two years, along with measures of acute rejection, proteinuria changes, and delayed graft function. This comprehensive approach supports long-term monitoring and future research on these kidney diseases.
CONDITIONS
Brief Title
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of FSGS or MCD in the native kidney before transplant
- Kidney transplant occurred from the year 2000 or later
- Consent to participate in the study or waiver of consent for retrospective data use
You will not qualify if you...
- Pathologic diagnosis other than FSGS or MCD
- FSGS or MCD caused by a known secondary disorder such as lupus nephritis, IgA nephropathy, or malignancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years after transplant
Participants who undergo routine care are observed to collect data and biospecimens including urine, blood, saliva, and kidney tissue to establish the RESOLVE biobank and understand the post-transplant course.
Visits scheduled according to routine post-transplant care; biospecimen collection and data recording occur during these visits
Trial Site Locations
Total: 1 location
1
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
Research Team
A
Ashley Rahimi
E
Eloise Salmon, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here